Asterias Biotherapeutics Inc (AST) Sees Large Drop in Short Interest

Asterias Biotherapeutics Inc (NYSEAMERICAN:AST) was the recipient of a large drop in short interest during the month of December. As of December 29th, there was short interest totalling 2,603,929 shares, a drop of 2.6% from the December 15th total of 2,672,506 shares. Based on an average daily volume of 143,188 shares, the days-to-cover ratio is currently 18.2 days. Approximately 8.2% of the shares of the company are short sold.

Asterias Biotherapeutics (AST) opened at $2.45 on Tuesday. Asterias Biotherapeutics has a 1 year low of $1.95 and a 1 year high of $5.00. The stock has a market cap of $132.67, a P/E ratio of -3.77 and a beta of 1.30.

Asterias Biotherapeutics (NYSEAMERICAN:AST) last posted its quarterly earnings results on Tuesday, November 14th. The biotechnology company reported ($0.15) earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of ($0.15). Asterias Biotherapeutics had a negative net margin of 403.38% and a negative return on equity of 79.80%.

AST has been the subject of a number of recent research reports. HC Wainwright reissued a “buy” rating and set a $12.00 price target on shares of Asterias Biotherapeutics in a research report on Monday, October 2nd. Zacks Investment Research raised shares of Asterias Biotherapeutics from a “hold” rating to a “buy” rating and set a $3.75 price target for the company in a research report on Tuesday, October 10th. One equities research analyst has rated the stock with a sell rating, one has given a hold rating and three have issued a buy rating to the stock. The company currently has a consensus rating of “Hold” and an average target price of $8.94.

TRADEMARK VIOLATION WARNING: “Asterias Biotherapeutics Inc (AST) Sees Large Drop in Short Interest” was originally posted by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are viewing this article on another site, it was copied illegally and republished in violation of U.S. & international copyright legislation. The original version of this article can be viewed at

About Asterias Biotherapeutics

Asterias Biotherapeutics, Inc is a biotechnology company. The Company is engaged in developing and commercializing therapies in the fields of cell therapy and regenerative medicine. The Company has over two technology platforms. The first is an immunotherapy platform to teach cancer patients’ immune systems to attack their tumors.

Receive News & Ratings for Asterias Biotherapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Asterias Biotherapeutics and related companies with's FREE daily email newsletter.

Leave a Reply